Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases

Maria Levitin; Joel Ofori; Woo Jae Shin; Jiayi Huang; Mackenzie Daly; Dengfeng Cao; Russell Pachynski

doi:10.3389/fonc.2020.566070

Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases

Maria Levitin, Joel Ofori, Woo Jae Shin, Jiayi Huang, Mackenzie Daly, Dengfeng Cao, Russell Pachynski

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically has poor prognosis, but the development of immune checkpoint inhibitors has revolutionized their care and may be successfully combined with SBRT to improve prognosis. Here, we present a case of a patient with mRCC who had brain metastases treated with concurrent immune checkpoint inhibitors and SBRT. He continues to survive with good functional status years following his initial diagnosis. We discuss the relevant history regarding treatment approach in patients with brain metastatic RCC, ongoing trials focusing on the combination of immunotherapy and radiation, and the potential and promise of the abscopal effect.

Original language	English
Article number	566070
Journal	Frontiers in Oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.566070
State	Published - Sep 23 2020

Keywords

SBRT (stereotactic body radiation therapy)
abscopal
brain metastases (BMs)
immunotherapy
renal cell carcinoma (RCC)

Access to Document

10.3389/fonc.2020.566070

Cite this

@article{743102588e8a4311bf3088f53ae69ea2,

title = "Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases",

abstract = "Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically has poor prognosis, but the development of immune checkpoint inhibitors has revolutionized their care and may be successfully combined with SBRT to improve prognosis. Here, we present a case of a patient with mRCC who had brain metastases treated with concurrent immune checkpoint inhibitors and SBRT. He continues to survive with good functional status years following his initial diagnosis. We discuss the relevant history regarding treatment approach in patients with brain metastatic RCC, ongoing trials focusing on the combination of immunotherapy and radiation, and the potential and promise of the abscopal effect.",

keywords = "SBRT (stereotactic body radiation therapy), abscopal, brain metastases (BMs), immunotherapy, renal cell carcinoma (RCC)",

author = "Maria Levitin and Joel Ofori and Shin, {Woo Jae} and Jiayi Huang and Mackenzie Daly and Dengfeng Cao and Russell Pachynski",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Levitin, Ofori, Shin, Huang, Daly, Cao and Pachynski.",

year = "2020",

month = sep,

day = "23",

doi = "10.3389/fonc.2020.566070",

language = "English",

volume = "10",

journal = "Frontiers in Oncology",

issn = "2234-943X",

}

TY - JOUR

T1 - Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases

AU - Levitin, Maria

AU - Ofori, Joel

AU - Shin, Woo Jae

AU - Huang, Jiayi

AU - Daly, Mackenzie

AU - Cao, Dengfeng

AU - Pachynski, Russell

PY - 2020/9/23

Y1 - 2020/9/23

N2 - Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically has poor prognosis, but the development of immune checkpoint inhibitors has revolutionized their care and may be successfully combined with SBRT to improve prognosis. Here, we present a case of a patient with mRCC who had brain metastases treated with concurrent immune checkpoint inhibitors and SBRT. He continues to survive with good functional status years following his initial diagnosis. We discuss the relevant history regarding treatment approach in patients with brain metastatic RCC, ongoing trials focusing on the combination of immunotherapy and radiation, and the potential and promise of the abscopal effect.

AB - Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically has poor prognosis, but the development of immune checkpoint inhibitors has revolutionized their care and may be successfully combined with SBRT to improve prognosis. Here, we present a case of a patient with mRCC who had brain metastases treated with concurrent immune checkpoint inhibitors and SBRT. He continues to survive with good functional status years following his initial diagnosis. We discuss the relevant history regarding treatment approach in patients with brain metastatic RCC, ongoing trials focusing on the combination of immunotherapy and radiation, and the potential and promise of the abscopal effect.

KW - SBRT (stereotactic body radiation therapy)

KW - abscopal

KW - brain metastases (BMs)

KW - immunotherapy

KW - renal cell carcinoma (RCC)

UR - http://www.scopus.com/inward/record.url?scp=85092195568&partnerID=8YFLogxK

U2 - 10.3389/fonc.2020.566070

DO - 10.3389/fonc.2020.566070

M3 - Article

C2 - 33072598

AN - SCOPUS:85092195568

SN - 2234-943X

VL - 10

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 566070

ER -

Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this